ContraFect Announces Pricing of $10.0 Million Registered Direct Offering and Concurrent Private Placement
Rhea-AI Summary
ContraFect Corporation (Nasdaq: CFRX) announced a securities purchase agreement with an institutional investor, enabling the purchase of approximately $10 million in common stock and associated warrants. Each share's effective purchase price is $4.00, with 128,000 shares and pre-funded warrants for 2,372,000 shares to be issued. Additionally, warrants to purchase up to 5,000,000 shares are part of a concurrent private placement. The offering is set to close around March 2, 2023, pending customary conditions. This transaction is executed under an existing shelf registration statement, focusing on funding for its direct lytic agents aimed at treating antibiotic-resistant infections.
Positive
- The offering raises $10 million, providing essential funding for ongoing development.
- The low purchase price of $4.00 per share may attract further institutional interest.
- Warrants allow for additional capital generation in the future.
Negative
- Issuing new shares and warrants could lead to shareholder dilution.
News Market Reaction
On the day this news was published, CFRX declined 26.79%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
YONKERS, N.Y., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, today announced that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately
Under the terms of the securities purchase agreement, ContraFect has agreed to issue 128,000 shares of common stock and pre-funded warrants to purchase 2,372,000 shares of common stock. In the concurrent private placement, which will be consummated concurrently with the offering, ContraFect also has agreed to issue warrants to purchase up to 5,000,000 shares of common stock. Each of the pre-funded warrants and the private placement warrants will be immediately exercisable, subject to a customary beneficial ownership limitation on exercisability. The private placement warrants expire five years from the date of issuance and have an exercise price of
Maxim Group LLC is acting as the sole placement agent for the offering.
The offering is expected to close on or about March 2, 2023, subject to the satisfaction of customary closing conditions.
The shares of common stock and pre-funded warrants are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-246359) previously filed and declared effective by the Securities and Exchange Commission (SEC) on August 31, 2020. The offering of the shares of common stock and pre-funded warrants will be made only by means of a prospectus supplement that forms a part of the registration statement. The warrants issued in the concurrent private placement and the shares issuable upon exercise of such warrants were offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), and/or Regulation D promulgated thereunder, have not been registered under the Act or applicable state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A prospectus supplement relating to the shares of common stock and pre-funded warrants will be filed by ContraFect with the SEC. When available, copies of the prospectus supplement relating to the registered direct offering, together with the accompanying prospectus, can be obtained at the SEC's website at www.sec.gov or from Maxim Group LLC, 300 Park Avenue, New York, NY 10022, Attention: Syndicate Department, or via email at syndicate@maximgrp.com or telephone at (212) 895-3745.
Forward-Looking Statements
This press release contains, and our officers and representatives may make from time to time, “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this release include, without limitation, statements regarding the consummation of the registered direct offering and concurrent private placement and the satisfaction of customary closing conditions with respect to the registered direct offering and concurrent private placement. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on ContraFect’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks, uncertainties and changes in circumstances that are difficult to predict and many of which are beyond ContraFect’s control, including, without limitation, that ContraFect has and expects to continue to incur significant losses, ContraFect’s need for additional funding, which may not be available, the occurrence of any adverse events related to the discovery, development and commercialization of ContraFect’s product candidates such as unfavorable clinical trial results, insufficient supplies of drug products, the lack of regulatory approval, or the unsuccessful attainment or maintenance of patent protection, changes in management may negatively affect ContraFect’s business and other important risks detailed under the caption “Risk Factors” in ContraFect's Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 and its other filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Any forward-looking statement made by ContraFect in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, ContraFect expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investor Relations Contacts:
Michael Messinger
ContraFect Corporation
Tel: 914-207-2300
Email: mmessinger@contrafect.com
FAQ
What is the value of the agreement announced by ContraFect Corporation on February 28, 2023?
How many shares and warrants are being issued in ContraFect's recent offering?
What is the expected closing date for ContraFect's offering?
What is the exercise price for the warrants in ContraFect's offering?
What is the purpose of ContraFect Corporation's stock offering?
